BioSpace News Archive

Getinge, a leading global supplier of medical technology products and systems, chose Orange Business Services to deploy a software-defined wide area network.

Genetron Holdings Limited announced that it will release thirteen new research findings at the 21st World Conference on Lung Cancer, which will be held virtually from January 28 to 31.

Itamar Medical Ltd., a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced the appointment of Scott P. Serota to its Board of Directors.

SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel potential treatments for multiple therapeutic areas, announced today that the Immune Tolerance group leader, Shinu John, PhD, will present new preclinical data from the company’s Tolerizing Antigen Carriers (SQZ™ TACs) platform in an invited talk at the Antigen-Specific Immune Tolerance (ASIT) Digital Summit taking place January 26, 2021

Pfizer Inc. (NYSE: PFE) announced today co-primary endpoint results from a recently completed post-marketing required safety study, ORAL Surveillance (A3921133; NCT02092467).

Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports progress with extending the shelf life of its more robust, next generation DABRA catheter, featuring a braided overjacket to improve deliverability when navigating tortuous anatomy.

IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 fourth quarter financial results before the market opens on Thursday, February 4 th . IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the European Medicines Agency (EMA) has completed the validation of GBT’s Marketing Authorization Application (MAA) for Oxbryta ® (voxelotor) tablets and started its standard review process.

Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the fourth quarter ended December 31, 2020 on Monday, February 8, 2021 .

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) , a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced that effective as of market open on January 29, 2021, its common shares have been approved for listing to the Nasdaq Global Market ® and will continue trading under the company’s current ticker symbol – PSTI.